Table 1.
Patients with ccRCC (n = 93) | Patients with RAML-wvf (n = 49) | P | |
---|---|---|---|
Age | 57 (33–84) | 54 (26–90) | 0.267 |
Gender | <0.001 | ||
Male | 67 (72.0) | 18 (36.7) | |
Female | 26 (28.0) | 31 (63.3) | |
Amount | 1 | ||
Single | 88 (94.6) | 46 (93.9) | |
Multiple | 5 (5.4) | 3 (6.1) | |
Growth pattern | 0.163 | ||
Pattern A | 20 (21.5) | 13 (26.5) | |
Pattern B | 71 (76.3) | 32 (65.3) | |
Pattern C | 2 (2.2) | 4 (8.2) | |
Pattern D | 0 (0) | 0 (0) | |
Contour | 0.175 | ||
Regular | 69 (74.2) | 31 (63.3) | |
Irregular | 24 (25.8) | 18 (36.7) | |
Edge | 0.184 | ||
Blurred | 35 (37.6) | 13 (26.5) | |
Clear | 58 (62.4) | 36 (73.5) | |
Wedge shape sign | <0.001 | ||
No | 82 (88.2) | 29 (59.2) | |
Yes | 11 (11.8) | 20 (40.8) | |
Round tumor-kidney interface | 0.353 | ||
No | 76 (81.7) | 43 (87.8) | |
Yes | 17 (18.3) | 6 (12.2) | |
Pseudocapsule | <0.001 | ||
No | 25 (26.9) | 45 (91.8) | |
Yes | 68 (73.1) | 4 (8.2) | |
Necrosis or cystic | <0.001 | ||
No | 30 (32.3) | 40 (81.6) | |
Yes | 63 (67.7) | 9 (18.4) | |
Calcification | 1 | ||
No | 90 (96.8) | 46 (95.8) | |
Yes | 3 (3.2) | 2 (3.2) | |
Heterogeneous tumor parenchyma in pre-enhancement scanning | 0.002 | ||
No | 74 (79.6) | 48 (98.0) | |
Yes | 19 (20.4) | 1 (2.0) | |
Degree of CT attenuation in pre-enhancement scanning | <0.001 | ||
Not-high | 63 (67.7) | 3 (6.1) | |
High | 30 (32.3) | 46 (93.9) | |
Enhancement in pre-enhancement scanning | <0.001 | ||
Homogeneous | 26 (28.0) | 34 (69.4) | |
Heterogeneous | 67 (72.0) | 15 (30.6) | |
Enhancement in CMP | <0.001 | ||
Homogeneous | 7 (7.5) | 35 (71.4) | |
Heterogeneous | 86 (92.5) | 14 (28.6) | |
Enhancement in NP | <0.001 | ||
Homogeneous | 18 (19.4) | 41 (83.7) | |
Heterogeneous | 75 (80.6) | 8 (16.3) | |
ESR 1 | <0.001 | ||
<1–1 | 44 (47.3) | 43 (87.8) | |
≥1 | 49 (52.7) | 6(12.2) | |
ESR 2 | 0.011 | ||
<1 | 78 (83.9) | 48 (98.0) | |
≥1 | 15 (16.1) | 1(2.0) | |
Enhancement pattern | <0.001 | ||
Fast-in-fast-out | 76 (81.7) | 20 (40.8) | |
Fast-in-slow-out | 10 (10.8) | 21 (42.9) | |
Persistent enhancement | 7 (7.5) | 8 (16.3) |